Targeting WNT2 secreted by CAFs restores DC differentiation and DC-mediated anti-tumor T cell responses in a CRC mouse model, enhancing the therapeutic effect of PD-1 antibodies [63]. This evidence concerns the gene PDCD1 and colorectal carcinoma.